Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Correction of Farsightedness in Children Study (CHICS)

This study has been completed.
American Academy of Optometry
Ohio Lions Eye Research Foundation
College of Optometrists in Vision Development
SUNY Research Foundation
Information provided by (Responsible Party):
Marjean Kulp, Ohio State University Identifier:
First received: May 9, 2007
Last updated: October 14, 2014
Last verified: October 2014
Hyperopia (farsightedness) has been reported to be associated with reduced visual perceptual and reading abilities. However, there is controversy regarding whether or not to prescribe for low to moderate amounts of hyperopia. The Correction of Hyperopia In Children Study (CHICS) is a placebo-controlled, randomized, masked investigation of the effect of spectacle correction for moderate amounts of hyperopia on visual function, symptoms, attention, and reading skills in children.

Condition Intervention
Device: Glasses for the correction of low to moderate farsightedness
Device: Glasses with placebo lens

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Correction of Hyperopia in Children Study

Resource links provided by NLM:

Further study details as provided by Marjean Kulp, Ohio State University:

Primary Outcome Measures:
  • Reading ability [ Time Frame: 6 week primary outcome ]
    Reading ability as measured by the Kaufman Test of Educational Achievement (K-TEA).

Secondary Outcome Measures:
  • Attention [ Time Frame: 6 week primary outcome ]
    Attention as measured by the Cognitive Assessment System.

  • Symptoms [ Time Frame: 6 week primary outcome ]
    Improvement in symptoms as measured by a standardized questionnaire.

  • Visual ability [ Time Frame: 6 week primary outcome ]
    Improvement in accommodative and/or vergence function.

Enrollment: 48
Study Start Date: November 2003
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Spectacles
Spectacles with hyperopic lenses
Device: Glasses for the correction of low to moderate farsightedness
Placebo Comparator: Control
Spectacles with placebo lenses
Device: Glasses with placebo lens


Ages Eligible for Study:   6 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 6-11 years;
  • At least +1.00D Hyperopia (farsightedness);
  • < +4.00D Hyperopia;
  • < 1.00D Astigmatism;
  • < 1.00D Anisometropia (difference between the two eyes);
  • Willing to be randomized;
  • Best corrected visual acuity of 20/25 or better in each eye;
  • Willing to wear eyeglasses full-time;
  • Willing to return for follow-up visits

Exclusion Criteria:

  • Previous wear of glasses or contacts for farsightedness/hyperopia;
  • Eye disease that affects visual function;
  • Amblyopia (lazy eye);
  • Strabismus (eye turn);
  • History of strabismus surgery;
  • Chronic use of any of the following medications:

    • Antianxiety agents (Librium, Valium)
    • Antiarrythmic agents (Cifenline, Cibenzoline)
    • Anticholinergics (Motion sickness patch - scopolamine)
    • Bladder spasmolytic (Propiverine)
    • Chloroquine
    • Phenothiazines (Compazine, Mellaril, Thorazine)
    • Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00472212

United States, Illinois
Illinois College of Optometry/Illinois Eye Institute
Chicago, Illinois, United States, 60616
United States, New York
SUNY College of Optometry/University Optometric Center
New York, New York, United States, 10036
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Tennessee
Southern College of Optometry
Memphis, Tennessee, United States, 38104
Sponsors and Collaborators
Ohio State University
American Academy of Optometry
Ohio Lions Eye Research Foundation
College of Optometrists in Vision Development
SUNY Research Foundation
Principal Investigator: Marjean Kulp, OD, MS Ohio State University
  More Information

Responsible Party: Marjean Kulp, Professor, Ohio State University Identifier: NCT00472212     History of Changes
Other Study ID Numbers: 2001H0401
Study First Received: May 9, 2007
Last Updated: October 14, 2014

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors processed this record on May 25, 2017